Skip to content

Study · Not a test of the peptide alone · 2020

10 results

Reduction of FoxP3+ Tregs by an immunosuppressive protocol of rapamycin plus Thymalfasin and Huaier extract predicts positive survival benefits in a rat model of hepatocellular carcinoma.

Zhou L, Pan LC, Zheng YG, Zhang XX, Liu ZJ, Meng X, Shi HD, Du GS, He Q

Annals of translational medicine1 Apr 2020Cited by 12 (Europe PMC)

PMID32395516 (opens in a new tab)PMCIDPMC7210174 (opens in a new tab)DOI10.21037/atm.2020.03.129 (opens in a new tab)PepBankPUB-32395516
Read at sourcePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with HCC relapse after liver transplant, rapamycin plus thymalfasin and Huaier extract alleviated hepatic pathological changes.

    In plain wordsIn rats, a regimen of rapamycin, thymalfasin and Huaier extract eased liver damage from tumor relapse.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseHepatic pathological changes
    Study

    ratn: not reported in source

    rat model of HCC relapse after liver transplant
    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    Combined therapy by RAPA plus Zadaxin and PS-T obviously alleviated hepatic pathological changes
    2 context sentences
    Summary · context
    We successfully established a rat model simulating HCC relapse after LT using an optimized chemical induction method with TACROLIMUS, methylprednisolone, and diethylnitrosamine as identified by visible liver nodules and hematoxylin-eosin staining.
    Summary · context
    The model rats were then treated with RAPA, Zadaxin, and PS-T.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with HCC relapse after liver transplant, rapamycin plus thymalfasin and Huaier extract lowered FoxP3+ Treg levels in blood, spleen and liver.

    In plain wordsIn rats, a regimen of rapamycin, thymalfasin and Huaier extract lowered regulatory T cells in blood, spleen and liver.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseFoxP3+ Tregs in blood, spleen and liver
    Study

    ratn: not reported in source

    rat model of HCC relapse after liver transplant
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Combined therapy by RAPA plus Zadaxin and PS-T obviously alleviated hepatic pathological changes and significantly decreased the levels of FoxP3+Tregs in peripheral blood, the spleen, and the liver (P<0.05)
    2 context sentences
    Summary · context
    We successfully established a rat model simulating HCC relapse after LT using an optimized chemical induction method with TACROLIMUS, methylprednisolone, and diethylnitrosamine as identified by visible liver nodules and hematoxylin-eosin staining.
    Summary · context
    The model rats were then treated with RAPA, Zadaxin, and PS-T.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism

    In rats with HCC relapse after liver transplant, rapamycin plus thymalfasin and Huaier extract decreased liver mTOR protein expression.

    In plain wordsIn rats, a regimen of rapamycin, thymalfasin and Huaier extract lowered mTOR protein in the liver.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreasemTOR protein expression in liver
    Study

    ratn: not reported in source

    rat model of HCC relapse after liver transplant
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    expression of mTOR protein (P<0.01)
    2 context sentences
    Summary · context
    We successfully established a rat model simulating HCC relapse after LT using an optimized chemical induction method with TACROLIMUS, methylprednisolone, and diethylnitrosamine as identified by visible liver nodules and hematoxylin-eosin staining.
    Summary · context
    The model rats were then treated with RAPA, Zadaxin, and PS-T.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with HCC relapse after liver transplant, rapamycin plus thymalfasin and Huaier extract improved survival time.

    In plain wordsIn rats, a regimen of rapamycin, thymalfasin and Huaier extract lengthened survival.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSurvival time
    Study

    ratn: not reported in source

    rat model of HCC relapse after liver transplant
    Outcome group
    Mortality · Cancer

    Source sentences

    Summary
    obviously improved survival time (P=0.02)
    2 context sentences
    Summary · context
    We successfully established a rat model simulating HCC relapse after LT using an optimized chemical induction method with TACROLIMUS, methylprednisolone, and diethylnitrosamine as identified by visible liver nodules and hematoxylin-eosin staining.
    Summary · context
    The model rats were then treated with RAPA, Zadaxin, and PS-T.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with HCC relapse after liver transplant, the regimen raised CD8+ T cells to almost normal levels compared with protocols without SRL monotherapy.

    In plain wordsIn rats, the regimen raised CD8+ T cell levels to almost normal, compared with protocols without rapamycin alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD8+ T cell levels
    Study

    ratn: not reported in source

    rat model of HCC relapse after liver transplant
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Moreover, the levels of CD8+T cells were increased significantly to almost normal levels (P<0.05) in comparison with no SRL monotherapy protocols.
    2 context sentences
    Summary · context
    We successfully established a rat model simulating HCC relapse after LT using an optimized chemical induction method with TACROLIMUS, methylprednisolone, and diethylnitrosamine as identified by visible liver nodules and hematoxylin-eosin staining.
    Summary · context
    The model rats were then treated with RAPA, Zadaxin, and PS-T.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with HCC relapse after liver transplant, SRL-based therapy decreased IL-10 compared with the other groups.

    In plain wordsIn rats, rapamycin-based therapy lowered IL-10 compared with the other groups.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseIL-10 level
    Study

    ratn: not reported in source

    rat model of HCC relapse after liver transplant
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    Significant decreases of IL-10 and TGF-β were observed after SRL-based therapy (P<0.01) in comparison with the other groups.
    2 context sentences
    Summary · context
    We successfully established a rat model simulating HCC relapse after LT using an optimized chemical induction method with TACROLIMUS, methylprednisolone, and diethylnitrosamine as identified by visible liver nodules and hematoxylin-eosin staining.
    Summary · context
    The model rats were then treated with RAPA, Zadaxin, and PS-T.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  7. 07AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with HCC relapse after liver transplant, SRL-based therapy decreased TGF-β compared with the other groups.

    In plain wordsIn rats, rapamycin-based therapy lowered TGF-β compared with the other groups.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseTGF-β level
    Study

    ratn: not reported in source

    rat model of HCC relapse after liver transplant
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    Significant decreases of IL-10 and TGF-β were observed after SRL-based therapy (P<0.01) in comparison with the other groups.
    2 context sentences
    Summary · context
    We successfully established a rat model simulating HCC relapse after LT using an optimized chemical induction method with TACROLIMUS, methylprednisolone, and diethylnitrosamine as identified by visible liver nodules and hematoxylin-eosin staining.
    Summary · context
    The model rats were then treated with RAPA, Zadaxin, and PS-T.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  8. 08AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with HCC relapse after liver transplant, serum alpha fetoprotein decreased significantly with the regimen of rapamycin, thymalfasin and Huaier extract.

    In plain wordsIn rats, the tumor marker AFP in blood fell after the regimen.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSerum AFP level
    Study

    ratn: not reported in source

    rat model of HCC relapse after liver transplant
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Serum alpha fetoprotein (AFP) and vascular endothelial growth factor (VEGF) levels were also decreased significantly (P<0.05).
    2 context sentences
    Summary · context
    We successfully established a rat model simulating HCC relapse after LT using an optimized chemical induction method with TACROLIMUS, methylprednisolone, and diethylnitrosamine as identified by visible liver nodules and hematoxylin-eosin staining.
    Summary · context
    The model rats were then treated with RAPA, Zadaxin, and PS-T.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  9. 09AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with HCC relapse after liver transplant, serum VEGF decreased significantly with the regimen of rapamycin, thymalfasin and Huaier extract.

    In plain wordsIn rats, VEGF in blood fell after the regimen.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSerum VEGF level
    Study

    ratn: not reported in source

    rat model of HCC relapse after liver transplant
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Serum alpha fetoprotein (AFP) and vascular endothelial growth factor (VEGF) levels were also decreased significantly (P<0.05).
    2 context sentences
    Summary · context
    We successfully established a rat model simulating HCC relapse after LT using an optimized chemical induction method with TACROLIMUS, methylprednisolone, and diethylnitrosamine as identified by visible liver nodules and hematoxylin-eosin staining.
    Summary · context
    The model rats were then treated with RAPA, Zadaxin, and PS-T.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  10. 10AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism

    In rats with HCC relapse after liver transplant, FoxP3+ Tregs correlated negatively with CD8+ and CD4+/CD8+ T cells and positively with AFP and VEGF.

    In plain wordsIn rats, regulatory T cells were linked to fewer CD8+ cells and higher AFP and VEGF.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableCorrelation of FoxP3+ Tregs with CD8+ cells, AFP and VEGF
    Study

    ratn: not reported in source

    rat model of HCC relapse after liver transplant
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    FoxP3+Tregs showed a negative correlation with CD8+ and CD4+/CD8+T cells and a positive correlation with AFP, and VEGF (P<0.05).
    2 context sentences
    Summary · context
    We successfully established a rat model simulating HCC relapse after LT using an optimized chemical induction method with TACROLIMUS, methylprednisolone, and diethylnitrosamine as identified by visible liver nodules and hematoxylin-eosin staining.
    Summary · context
    The model rats were then treated with RAPA, Zadaxin, and PS-T.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.